Literature DB >> 8471427

Gallium-67 radiotoxicity in human U937 lymphoma cells.

A R Jonkhoff1, P C Huijgens, R T Versteegh, E B van Dieren, G J Ossenkoppele, H J Martens, G J Teule.   

Abstract

Promising clinical results have been obtained with radiolabeled antibodies in lymphoma patients. The higher uptake by lymphomas of 67Gallium (67Ga) compared with monoclonal antibodies makes selective radiotherapy by the widely available 67Ga appealing. However, the gamma radiation of 67Ga used in scintigraphy is considered to be almost non-toxic to lymphoma cells. However, in addition to photon radiation 67Ga emits low energy Auger electrons and 80-90 keV conversion electrons which could be cytotoxic. The objective of the present study was the assessment of radiotoxicity of 67Ga on a lymphoid cell line: U937. Proliferation (MTT-assay) and clonogenic capacity (CFU-assay) were measured after 3 and 6 days incubation with 10, 20 and 40 microCi ml-1 67Ga. Growth inhibition was 36% after 3 days incubation and 63% after 6 days incubation with 40 microCi 67Ga ml-1. Clonogenic capacity was reduced by 51% after 3 days and 72% after 6 days incubation with 40 microCi ml-1 67Ga. A survival curve showed an initial shoulder and became steeper beyond 200-250 pCi cell-1 (low linear energy transfer type). Iso-effect doses of 67Ga and 90Yttrium (90Y) were determined. The iso-effect dose of 40 microCi 67Ga ml-1 (cumulative dose of conversion electrons 306 cGy) was 2.5 microCi 90Y ml-1 (cumulative dose 494 cGy) and the iso-effect dose of 80 microCi 67Ga ml-1 was 5.0 microCi 90Y/ml. The main cytotoxic effect of 67Ga seems to be induced by the 80 keV conversion electrons. We conclude that the conversion electrons of 67Ga have a cytotoxic effect on U937 cells and that in our experiments a 16-fold higher microCi-dose of 67Ga than of 90Y was needed for the same cytotoxic effect. We believe that 67Ga holds promise for therapeutic use.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471427      PMCID: PMC1968343          DOI: 10.1038/bjc.1993.128

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.

Authors:  D M Goldenberg; J A Horowitz; R M Sharkey; T C Hall; S Murthy; H Goldenberg; R E Lee; R Stein; J A Siegel; D O Izon
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

2.  Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.

Authors:  H M Vriesendorp; J M Herpst; M A Germack; J L Klein; P K Leichner; D M Loudenslager; S E Order
Journal:  J Clin Oncol       Date:  1991-06       Impact factor: 44.544

3.  Use of the tetrazolium assay in measuring the response of human tumor cells to ionizing radiation.

Authors:  P Price; T J McMillan
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

4.  Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay.

Authors:  P R Twentyman; N E Fox; J K Rees
Journal:  Br J Haematol       Date:  1989-01       Impact factor: 6.998

5.  Whole-body retention of 67Ga-citrate.

Authors:  E E Watson; R J Cloutier; W D Gibbs
Journal:  J Nucl Med       Date:  1973-11       Impact factor: 10.057

6.  Imaging of T-cell lymphoma by radiolabelled monoclonal antibody.

Authors:  P A Bunn; J A Carrasquillo; A M Keenan; R W Schroff; K A Foon; S M Hsu; A F Gazdar; J C Reynolds; P Perentesis; S M Larson
Journal:  Lancet       Date:  1984-11-24       Impact factor: 79.321

7.  Prolonged "ultra" low-dose-rate irradiation: effects on Chinese hamster cell population growth, survival, and radiation sensitivity.

Authors:  W U Shipley; M Jennings; L E Gerweck; C C Ling
Journal:  Radiat Res       Date:  1981-01       Impact factor: 2.841

8.  Distribution of gallium in human tissues after intravenous administration.

Authors:  B Nelson; R L Hayes; C L Edwards; R M Kniseley; G A Andrews
Journal:  J Nucl Med       Date:  1972-01       Impact factor: 10.057

9.  Rdiotoxicity of intracellular 67Ga, 125I and 3H. Nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia.

Authors:  K G Hofer; C R Harris; J M Smith
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1975-09

10.  Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody.

Authors:  J A Carrasquillo; P A Bunn; A M Keenan; J C Reynolds; R W Schroff; K A Foon; M H Su; A F Gazdar; J L Mulshine; R K Oldham
Journal:  N Engl J Med       Date:  1986-09-11       Impact factor: 91.245

View more
  7 in total

1.  Radiolabelling DOTA-peptides with 68Ga.

Authors:  Wouter A P Breeman; Marion de Jong; Erik de Blois; Bert F Bernard; Mark Konijnenberg; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-18       Impact factor: 9.236

2.  Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy.

Authors:  W H Bakker; W A Breeman; M E van der Pluijm; M de Jong; T J Visser; E P Krenning
Journal:  Eur J Nucl Med       Date:  1996-07

3.  In vitro cytotoxicity of Auger electron-emitting [67Ga]Ga-trastuzumab.

Authors:  Muhamad Faiz Bin Othman; Elise Verger; Ines Costa; Meena Tanapirakgul; Margaret S Cooper; Cinzia Imberti; Valerie J Lewington; Philip J Blower; Samantha Y A Terry
Journal:  Nucl Med Biol       Date:  2019-12-13       Impact factor: 2.408

Review 4.  A nuclear chocolate box: the periodic table of nuclear medicine.

Authors:  Philip J Blower
Journal:  Dalton Trans       Date:  2015-03-21       Impact factor: 4.390

5.  Effect of modulation of the transferrin receptor on gallium-67 uptake and cytotoxicity in lymphoma cell lines.

Authors:  A E van Leeuwen-Stok; G J Schuurhuis; A M Dräger; A W Visser-Platier; G J Teule; P C Huijgens
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

6.  High-dose gallium-67 therapy in patients with relapsed acute leukaemia: a feasibility study.

Authors:  A R Jonkhoff; M A Plaizier; G J Ossenkoppele; G J Teule; P C Huijgens
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

7.  Re-assessing gallium-67 as a therapeutic radionuclide.

Authors:  Muhamad F Bin Othman; Nabil R Mitry; Valerie J Lewington; Philip J Blower; Samantha Y A Terry
Journal:  Nucl Med Biol       Date:  2016-10-29       Impact factor: 2.408

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.